Population pharmacokinetics of exenatide

British Journal of Clinical Pharmacology

Volumn 83, Issue 3, 2017, Pages 517-526

  Cirincione, Brenda ^a,b   Mager, Donald E ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

exenatide; pharmacokinetics; renal impairment; type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL (TOPIC); COMPARTMENT MODEL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG RELEASE; FEMALE; HUMAN; IMMEDIATE DRUG RELEASE; MAJOR CLINICAL STUDY; MALE; MICHAELIS MENTEN KINETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RENAL CLEARANCE; SIMULATION; STANDARD; SUSTAINED RELEASE FORMULATION; ADOLESCENT; BIOLOGICAL MODEL; COMPUTER SIMULATION; DOSE RESPONSE; MIDDLE AGED; NONLINEAR SYSTEM; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PEPTIDES; VENOMS; YOUNG ADULT;

EID: 85002843758     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13135     Document Type: Article

References (39)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44 (Database Issue): D1054–D1068.
2. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 2015; 172: 5744–5869.
3. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 2015; 172: 6024–6109.
4. Byetta (exenatide) injection: US prescribing information. Wilmington, DE: AstraZeneca LP; 2014.
5. Bydureon (exenatide extended-release for injectable suspension): US prescribing information. Wilmington, DE: AstraZeneca LP; 2014.
6. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008; 294: E846–E852.
7. MacConell L, Malloy J, Huang W, Cirincione B, Shen L, Porter L. Safety and efficacy of once-monthly exenatide administration over 20 weeks in patients with type 2 diabetes. Diabetes 2011; 60: LB13–LB14.
8. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011; 13: 1145–1154.
9. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77–88.
10. Vilsbøll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88: 220–224.
11. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006; 7: 367–374.
12. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317–327.
13. US Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function – study design, data analysis, and impact on dosing and labeling (draft guidance - revision 1); 2010 [online]. Available at http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf (last accessed 8 October 2014).
14. Chen T, Mager DE, Kagan L. Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm Res 2013; 30: 751–760.
15. Gao W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther 2011; 336: 881–890.
16. Gao W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metab Dispos 2012; 40: 990–997.
17. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507–532.
18. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994; 56: 248–252.
19. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 2001; 53: 260–267.
20. Tatarkiewicz K, Sablan E, Polizzi C, Parkes D. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide-1 receptor. Diabetes 2011; 60: A480.
21. Darpo B, Sager P, MacConell L, Cirincione B, Mitchell M, Han J, et al. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol 2013; 75: 979–989.
22. Fineman M, Phillips L, Jaworowicz DJ, Cirincione B, Ludwig E, Taylor K, et al. Model-based evaluations to select and confirm doses in the clinical development of exenatide. Clin Pharmacol Ther 2007; 81: S111.
23. Phillips L, Fineman M, Taylor K, Baron A, Ludwig E, Grasela T. Population modeling to guide phase 3 dose selection for AC2993 (synthetic exendin-4). Clin Pharmacol Ther 2002; 71: P29.
24. US Food and Drug Administration. Guidance for industry: bioanalytical method validation; 2001 [online]. Available at http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf (last accessed 8 October 2014).
25. Xu XS, Yuan M, Karlsson MO, Dunne A, Nandy P, Vermeulen A. Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J 2012; 14: 927–936.
26. Holford N. The visual predictive check – superiority to standard diagnostic (Rorschach) plots. Paper presented at: PAGE 142005.
27. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628–2635.
28. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092–1100.
29. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083–1091.
30. Yan X, Mager DE, Krzyzanski W. Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 2010; 37: 25–47.
31. Linnebjerg H, Kothare PA, Seger M, Wolka AM, Mitchell MI. Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥75 years of age with type 2 diabetes. Int J Clin Pharmacol Ther 2011; 49: 99–108.
32. Bhavsar S, Mudaliar S, Cherrington A. Evolution of exenatide as a diabetes therapeutic. Curr Diabetes Rev 2013; 9: 161–193.
33. Kagan L. Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins. Drug Metab Dispos 2014; 42: 1890–1905.
34. Watson E, Jonker DM, Jacobsen LV, Ingwersen SH. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol 2010; 50: 886–894.
35. Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14: 546–554.
36. Perez Ruixo JJ, Ma P, Chow AT. The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. AAPS J 2013; 15: 172–182.
37. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173–181.
38. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082–3089.
39. Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005; 27: 210–215.